Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib-Reference-Cited by-同舟云学术

Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib

Published:2011-03 Issue:3 Volume:32 Page:399-407
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Dong Pei-pei,Fang Zhong-ze,Zhang Yan-yan,Ge Guang-bo,Mao Yu-xi,Zhu Liang-liang,Qu Yan-qing,Li Wei,Wang Li-ming,Liu Chang-xiao,Yang Ling

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.nature.com/articles/aps2010218.pdf

Reference48 articles.

1. Ciardiello F, Tortora G . A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958–70.

2. Smith J . Erlotinib: Small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther 2005; 27: 1513–34.

3. Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–32.

4. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R . FDA drug approval summary: Erlotinib (Tarceva (R)) tablets. Oncologist 2005; 10: 461–6.

5. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2007; 25: 1960–6.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Drug-Drug Interaction between Erlotinib and OSI-930 Is Mediated through Aldehyde Oxidase Inhibition;Drug Metabolism and Disposition;2024-06-18

2. Probe Substrate Dependencies in CYP3A4 Allosteric Inhibition: A Novel Molecular Mechanism Involving F–F′ Loop Perturbations;Journal of Chemical Information and Modeling;2024-03-08

3. Humanization ofSLCO2B1in Rats Increases rCYP3A1 Protein Expression but Not the Metabolism of Erlotinib to OSI-420;Journal of Pharmacology and Experimental Therapeutics;2024-03-06

4. Substrate-selective small-molecule modulators of enzymes: Mechanisms and opportunities;Current Opinion in Chemical Biology;2023-02

5. Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug–drug–disease interactions with protein kinase inhibitors in cancer‐associated venous thromboembolism;British Journal of Clinical Pharmacology;2022-01-05